Antimicrobial Agents and Chemotherapy · 2015 · 27 citations · 36 references
Life SciencesImmunologyPharmacologyAntimicrobial PharmacologyAutophagyImmunopharmacologyAntibacterial AgentsAutophagy In DiseaseAutophagy In ImmunityAutophagy ModulationMacrophage BiologyTuberculosis PharmacotherapyAnti-tuberculosis Drug RepurposingAutophagy In TuberculosisAutophagy PathwayBacterial Efflux PumpsDrug Efflux PumpsInterferon Gamma ProductionMycobacterium Tuberculosis InfectionVerapamil Therapy
There is a growing interest in repurposing mycobacterial efflux pump inhibitors, such as verapamil, for tuberculosis (TB) treatment. To aid in the design of better analogs, we studied the effects of verapamil on macrophages and Mycobacterium tuberculosis-specific T cells. Macrophage activation was evaluated by measuring levels of nitric oxide, tumor necrosis factor alpha (TNF-α), interleukin-1 beta (IL-1β), and gamma interferon (IFN-γ). Since verapamil is a known autophagy inducer, the roles of autophagy induction in the antimycobacterial activities of verapamil and norverapamil were studied using bone marrow-derived macrophages from ATG5(flox/flox) (control) and ATG5(flox/flox) Lyz-Cre mice. Our results showed that despite the well-recognized effects of verapamil on calcium channels and autophagy, its action on intracellular M. tuberculosis does not involve macrophage activation or autophagy induction. Next, the effects of verapamil and norverapamil on M. tuberculosis-specific T cells were assessed using flow cytometry following the stimulation of peripheral blood mononuclear cells from TB-skin-test-positive donors with M. tuberculosis whole-cell lysate for 7 days in the presence or absence of drugs. We found that verapamil and norverapamil inhibit the expansion of M. tuberculosis-specific T cells. Additionally, three new verapamil analogs were found to inhibit intracellular Mycobacterium bovis BCG, and one of the three analogs (KSV21) inhibited intracellular M. tuberculosis replication at concentrations that did not inhibit M. tuberculosis-specific T cell expansion. KSV21 also inhibited mycobacterial efflux pumps to the same degree as verapamil. More interestingly, the new analog enhances the inhibitory activities of isoniazid and rifampin on intracellular M. tuberculosis. In conclusion, KSV21 is a promising verapamil analog on which to base structure-activity relationship studies aimed at identifying more effective analogs.
36
Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice
Taichi Hara, Kenji Nakamura, Makoto Matsui et al. · Nature · 2006 · 3.8K citations
Charles L. Daley, Peter M. Small, Gisela Schecter et al. · New England Journal of Medicine · 1992 · 996 citations · Full text
Drug Tolerance in Replicating Mycobacteria Mediated by a Macrophage-Induced Efflux Mechanism
Kristin N. Adams, Kevin K. Takaki, Lynn Connolly et al. · Cell · 2011 · 536 citations · Full text